NASDAQ:RADX Radiopharm Theranostics Q4 2026 Earnings Report $1.75 +0.02 (+1.10%) Closing price 09/18/2026 03:56 PM EasternExtended Trading$1.71 -0.04 (-2.23%) As of 09/18/2026 07:30 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. ProfileEarnings HistoryForecast Radiopharm Theranostics EPS ResultsActual EPS-$0.81Consensus EPS N/ABeat/MissN/AOne Year Ago EPSN/ARadiopharm Theranostics Revenue ResultsActual Revenue$0.49 millionExpected RevenueN/ABeat/MissN/AYoY Revenue GrowthN/ARadiopharm Theranostics Announcement DetailsQuarterQ4 2026Date7/31/2026TimeBefore Market OpensConference Call DateN/AConference Call TimeN/AConference Call ResourcesEarnings HistoryCompany Profile Radiopharm Theranostics Earnings HeadlinesRadiopharm Theranostics (NASDAQ:RADX) Trading 1.1% Higher - Should You Buy?September 19 at 1:41 AM | americanbankingnews.comRadiopharm Selected For Late-Breaking Presentation Of Positive RAD101 Phase 2b Data; Stock UpSeptember 14, 2026 | rttnews.comA new kind of civil war is coming after election day?Across America, AI-driven backlash is fueling protests, lawsuits, and moratoria that could reshape the political and investment landscape. Whitney Tilson believes tensions may come to a head at midnight on November 4th, the day after the midterm elections, with major implications for your portfolio.September 20 at 1:00 AM | Stansberry Research (Ad)Radiopharm Theranostics Selected for Late-Breaking Oral Presentation of Positive Data from Interim Analysis of U.S. Phase 2b Imaging Trial of RAD101 at 2026 Society of Neuro ...September 14, 2026 | finance.yahoo.comRadiopharm Theranostics Reports Positive Phase 1 Imaging Data For RAD 301 In Pancreatic CancerSeptember 9, 2026 | rttnews.comRadiopharm Theranostics Announces Positive Data from the Phase 1 Imaging Trial of RAD301 in Patients with Pancreatic Ductal AdenocarcinomaSeptember 9, 2026 | globenewswire.comSee More Radiopharm Theranostics Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Radiopharm Theranostics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Radiopharm Theranostics and other key companies, straight to your email. Email Address About Radiopharm TheranosticsRadiopharm Theranostics (NASDAQ:RADX) Limited (NASDAQ: RADX) is an Australian clinical-stage biopharmaceutical company focused on developing radiopharmaceuticals for the diagnosis and treatment of cancer. Its approach combines tumor-targeting molecules with radioactive isotopes to help identify cancer, assess disease progression and deliver targeted radiation to malignant cells. The company’s pipeline includes investigational diagnostic and therapeutic radiopharmaceuticals based on peptide and antibody platforms. These programs are designed to address a range of cancers and may support applications such as patient selection, disease monitoring and targeted radionuclide therapy. Radiopharm Theranostics is advancing its candidates through preclinical development and clinical trials. Radiopharm Theranostics is headquartered in Australia and has pursued research and clinical-development activities in international markets, including the United States. The company is led by Managing Director and Chief Executive Officer Paul Hopper, who has experience in biotechnology and the development of healthcare companies.View Radiopharm Theranostics ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles J.B. Hunt's Stock Plunges After Market Misprices Profit WarningLennar’s Earnings Miss May Be Sending a Bigger Warning About U.S. HousingThese 3 Stocks Sit at the Center of NVIDIA’s Cybersecurity PushLennar's Q3 Miss Hides a Stronger Operating Story Beneath the Housing SlumpAeluma’s Selloff Could Be Setting Up Its Next Big MoveBraze Beat Expectations—Now 2 SaaS Peers Are in FocusPriced for a Pullback or More Gains? These 3 Stocks Are Testing the Limits Upcoming Earnings Cintas (9/23/2026)Costco Wholesale (9/24/2026)Micron Technology (9/30/2026)NIKE (10/1/2026)Accenture (10/1/2026)PepsiCo (10/8/2026)Delta Air Lines (10/9/2026)America Movil (10/13/2026)BlackRock (10/13/2026)Citigroup (10/13/2026) Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
